About: Longitudinal analysis of the quality of life (QoL) within a randomized phase III trial: Octreotide versus placebo for the patients having advanced hepatocellular carcinoma (HCC)   Goto Sponge  NotDistinct  Permalink

An Entity of Type : owl:Thing, within Data Space : data.idref.fr associated with source document(s)

AttributesValues
Author
Bibliographic Citation
  • Dumas F., Barbare J., Aparicio T., Bouché O., Lombard-Bohas C., Faroux R., Seitz J., Raoul J., Bedenne L., Bonnetain F.. Longitudinal analysis of the quality of life (QoL) within a randomized phase III trial: Octreotide versus placebo for the patients having advanced hepatocellular carcinoma (HCC). Journal of Clinical Oncology, American Society of Clinical Oncology, 2009, 27 (15, S)
  • DumasF., BarbareJ., AparicioT., BouchéO., Lombard-BohasC., FarouxR., SeitzJ., RaoulJ., BedenneL., BonnetainF.. Longitudinal analysis of the quality of life (QoL) within a randomized phase III trial: Octreotide versus placebo for the patients having advanced hepatocellular carcinoma (HCC). Journal of Clinical Oncology, American Society of Clinical Oncology, 2009, 27 (15, S)
Title
  • Longitudinal analysis of the quality of life (QoL) within a randomized phase III trial: Octreotide versus placebo for the patients having advanced hepatocellular carcinoma (HCC)
dc:date
  • 2009
Faceted Search & Find service v1.13.91 as of Aug 16 2018


Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of May 14 2019, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (70 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software